Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Biodegradable reduce expenditure bioreactor for augmented sonodynamic therapy via regulating tumor hypoxia and inducing pro-death autophagy

Fig. 3

Intracellular uptake, hypoxia alleviation, and SDT efficacy of HHBP. a The relative viabilities of HUVEC, 4T1, A375, and A549 cells after incubation with HMONs-PEG nanoparticles (concentrations of 25, 50, 100, 200, and 250 µg/mL) for 24 h. b CLSM images of 4T1 cells incubated with FITC-conjugated HHBP for 1, 2, 4, and 8 h without or with US irradiation. Scale bar = 25 μm. c Western blotting results of HIF-1α and HK-II expression in 4T1 cells after different treatments. Fluorescence images of 4T1 cells after different treatments and staining with d JC-1 dye and e an intracellular ROS probe, DCFH-DA. Scale bar = 50 and 100 μm. f Flow cytometry data showing intracellular total ROS after different treatments. In panels d, e, and f treatment groups are denoted as: (I) PBS, (II) HMME@HMONs-PEG, (III) HHBP, (IV) PBS + US, (V) HMME@HMONs-PEG + US and (VI) HHBP + US

Back to article page